Quantitative analysis detects ubiquitous expression of apoptotic regulators in B cell non-Hodgkin's lymphomas

Leukemia

Volumn 13, Issue 10, 1999, Pages 1548-1553

  Xerri, L ^a,b   Devilard, E ^a,b   Bouabdallah, R ^a   Hassoun, J ^a   Chaperot, L ^c   Birg, F ^b   Plumas, J ^c  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c INSTITUT ALBERT BONNIOT   (France)

Author keywords

Bcl 2 homologues; Expression; Non Hodgkin's lymphoma; Western blotting

Indexed keywords

PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUANTITATIVE ASSAY; STATISTICS; TONSIL; TUMOR BIOPSY; WESTERN BLOTTING;

EID: 0032878342     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401533     Document Type: Article

References (38)

1. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
2. Lee Harris N, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. Cloning the chromosomal breakpoint of t(14;18) in human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899-906.
4. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and hybrid bcl-2 immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19-28.
5. Oltvai ZN, Millman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
6. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for bcl-xS and bcl-2, displaces bax and promotes cell death. Cell 1995; 80: 285-291.
7. Chittenden T, Harrington EA, O'Connor R, Flemington C, Luttz RJ, Evan GI, Guild BC. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-736.
8. Boise LH, Gonzales-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
9. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 1993; 90: 3516-3520.
10. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. Cloning and functional analysis of BAG-1: a novel Bcl-2 binding protein with anti-cell death activity. Cell 1995; 80: 279-284.
11. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG, Reed JC. Interactions among members of the Bcl-2 protein family analysed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994; 91: 9238-9246.
12. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-192.
13. Knudson CM, Korsmeyer SJ. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 1997; 16: 358-363.
14. Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod J, Mazzei G. Inhibition of Bax channel forming activity by Bcl-2. Science 1997; 277: 370-374.
15. Schlessinger P, Gross A, Yin XM, Yamamoto K, Saito M, Waksman G, Korsmeyer S. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 1997; 94: 11357-11361.
16. The non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of the Working Formulation for Clinical Usage. Cancer 1982; 49: 2112-2135.
17. Lennert K, Feller AC. Histopathology of Non-Hodgkin's Lymphomas, 2nd edn. Springer-Verlag: Berlin, 1992.
18. Hermine O, Haioun C, Lepage E, d'Agay MF, Brière J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard P. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
19. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 3173-3178.
20. Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p 53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997; 89: 2986-2993.
21. Salomons GS, Brady HJM, Verwijs-Janssen M, Van den Berg JD, Hart AAM, Van den Berg H, Behrendt H, Hählen K, Smets L. The Baxα:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukemia. Int J Cancer 1997; 71: 959-965.
22. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogeneous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156: 2624-2630.
23. Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MRA, Begleiter A. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997; 26: 435-449.
24. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76: 935-938.
25. Xerri L, Bouabdallah R, Devilard E, Hassoun J, Stoppa AM, Birg F. Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br J Cancer 1998; 78: 225-232.
26. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998; 91: 2875-2885.
27. Pagès F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, Olive D. Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994; 369: 327-329.
28. Ghiotto-Ragueneau M, Battifora M, Truneh A, Waterfield MD, Olive D. Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production. Eur J Immunol 1996; 26: 34-41.
29. Schlaifer D, Krajewski S, Galoin C, Rigal-Huguet F, Laurent G, Massip P, Pris J, Delsol G, Reed JC, Brousset P. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human deficiency virus infection. Am J Pathol 1995; 149: 177-185.
30. Defrance T, Billian G, Krammer PH, Lagresle C. Fas-dependent and Fas-independent mechanisms for selection of the mature human B cell repertoire. Ann NY Acad Sci 1997; 815: 67-74.
31. Yang XF, Weber GF, Cantor H. A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Cell 1997; 7: 629-639.
32. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994; 88: 238-274.
33. Panayiotidis P, Ganeshaguru L, Jabbar SAG, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993; 85: 439-447.
34. Long BW, Witte PL, Abraham GN, Gregory SA, Plate JM. Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells. Proc Natl Acad Sci USA 1995; 92: 1416-1423.
35. Holder MJ, Wang H, Milner AE, Casamayor M, Armitage R, Spriggs MK, Fanslow WC, MacLennan ICM, Gregory CD, Gordon J. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol 1993; 23: 2368-2371.
36. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, Shabaik A, Tudor G, Krajewski S, Myers TG, Johnson GS, Sausville EA, Reed JC. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998; 152: 51-61.
37. Xerri L, Parc P, Brousset P, Schlaifer D, Hassoun J, Reed JC, Krajewski S, Birnbaum D. Predominant expression of the long isoform of BCL-X (BCL-XL) in human lymphomas. Br J Haematol 1996; 92: 900-906.
38. Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91: 244-251.